Antioxidant status in patients with psoriasis

Cell Biochemistry and Function

Volumn 32, Issue 3, 2014, Pages 268-273

  Houshang, Nemati ^a   Reza, Khodarahmi ^b,c   Sadeghi, Masoud ^c   Ali, Ebrahimi ^d   Mansour, Rezaei ^d   Vaisi Raygani, Asad ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidant; Apolipoproteins; Lipids; Oxidant; Psoriasis

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; BILIRUBIN; BILIRUBIN GLUCURONIDE; CATALASE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN A; MALONALDEHYDE; SUPEROXIDE DISMUTASE; URIC ACID; APOA1 PROTEIN, HUMAN; ARYLDIALKYLPHOSPHATASE; PON1 PROTEIN, HUMAN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOPRECIPITATION; LIPID PEROXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; URIC ACID BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; YOUNG ADULT;

ADULT; ANTIOXIDANTS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; ARYLDIALKYLPHOSPHATASE; BILIRUBIN; CASE-CONTROL STUDIES; CATALASE; FEMALE; HUMANS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; PSORIASIS; SUPEROXIDE DISMUTASE; URIC ACID; YOUNG ADULT;

EID: 84898029845     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.3011     Document Type: Article

References (31)

1. Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinant of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 2004; 51: 704-708.
2. Gottieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21.
3. Vanizor Kural B, Orem A, Cimsit GU, Yandi YE, Calapoglu M. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clini Chim Acta 2003; 328: 71-82.
4. Kavanagh GM, Burton JL, Dannell VO. Effects of dithranol on neutrophil superoxide generation in patient with psoriasis. Br J Dermatol 1996; 134: 234-237.
5. Severin E, Nave B, Stander M, Ott R, Traupe H. Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology 1999; 198: 336-339.
6. Corrocher R, Ferrari S, Gironcoli M, Bassi A, Olivieri O, Guarini P, et al. Effect of fish oil supplementation on erythrocyte lipid pattern, malondialdehyde production and glutathione-peroxidase activity in psoriasis. Clin Chim Acta 1989; 179: 121-32.
7. Yousefi M, Rahimi H, Barikbin B, et al. Uric acid: A new antioxidant in patients with pemphigus vulgaris. Indian J Dermatol 2011; 56(3): 278-281.
8. Aysun Toker A, Kadi M, Yildirim K, Aksoy H, Akc F. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-80.
9. Baz K, Cimen MYB, Kokturk A, et al. Oxidant/antioxidant status in patients with psoriasis. Yonsei Med J 2003; 44(6): 987-90.
10. Ivanova IP, Mareeva TE. Disorders of lipid peroxidation and of lysosomal hydrolase activity and their correction in psoriasis patients. Vestn Dermatol Venereol 1987; 4: 26-31.
11. Walldius G, Jungner I. The apo B/apo A-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid - lowering therapy a review of the evidence. J Intern Med 2006; 259: 493-519.
12. Tam LS, Tomlinson B, Chu TT, et al. Cardiovascular risk profile of patients with psoriatic arthritis compared to controls-the role of inflammation. Rheumatology 2008; 47: 718-723.
13. Pietrzak A, Kadzielewski J, Janowski K, et al. Lipoprotein (a) in patients with psoriasis: associations with lipid profiles and disease severity. Int J Dermatol 2009; 48(4): 379-387.
14. Uyanik BS, Ari Z, Onur E, Gündüz K, Tanülkü S, Durkan K. Serum lipids and apolipoproteins in patients with psoriasis. Clin Chem Lab Med 2002; 40(1): 65-68.
15. Piskin S, Gurkok F, Ekuklu G, Senol M. Serum lipid levels in psoriasis. Yonsei Med J 2003; 44(1): 24-26.
16. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81-128.
17. Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases-what's new? JEADV 2003; 17: 663-669.
18. Rocha Pereira P, Silva I, Rebelo AS, Figneredo A, Quintanilhas A, Teixeira F. Erythrocyte damage in mild and severe psoriasis. British J. of Dermatol 2004; 150: 232-244.
19. Relhan V, Gupta S, Dayal S, Pandde R, Lal H. Blood thiol and Malondialdehyde level in psoriasis. The J. of Dermatol 2002; 29: 399-403.
20. Dipali PK, Adinath NS, Rajesh DA, Charushila YK, Kishor HD. Role of Oxidative Stress in various Stage of psoriasis. Ind J Clin Biochem 2010; 25(4): 388-392.
21. Pujari VM, Suryakar AN, Ireddy S. Oxidants and anti-oxidant status in psoriasis patients. Biomedical Res 2010; 21(2): 221-223.
22. Mackness M, Durrington P, Mackness B. Paraoxonase- 1 activity, concentration and genotype in cardiovascular disease. Curr Opin Lipidol 2004; 15: 399-404.
23. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: Are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 2001; 21: 1451-1457.
24. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. J Clin Endocrinol Metab 2004; 89: 2957-2962.
25. Jiang XL, Li M, Zhou JG, Yang OB, Du LJ, Du J. Plasma Paraoxonase-1, Oxidized Low-Density Lipoprotein and Lipid Peroxidation Levels in Gout Patients. Cell Biochem Biophys 2011; 61: 461-466.
26. Durak I, Canbolat O, Kavutcu M, Ozturk HS, Yurtarslani Z. Activities of total, cytoplasmic, and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal 1996; 10: 17-20.
27. Kobayashi T, Matsumoto M, Ilzuka H, Suzuki K, Taniguchi N. Superoxide dismutase in psoriasis, squamous cell carcinoma and basal cell epithelioma: an immunohistochemical study. Br J Dermatol 1991; 124(6): 555-559.
28. Waring WS. Uric acid: An important antioxidant in acute ischaemic stroke. QJM 2002; 95: 691-3.
29. Kwon HH, Kwon IH, Choi JW, Youn JI. Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis. Clin Exp Dermatol 2011; 36(5): 473-478.
30. Greenberg DA. The jaundice of the cell. Proc Narl Acad Sci 2002; 99(25): 15837-39.
31. James RW, Deakin SP. The importance of highdensity lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med 2004; 37: 1986-1994.